Fully Silent Fc-Engineered Antibodies

New partnership provides easy access to novel Fc silencing technology

A new partnership provides Absolute Antibody clients with easy license-free access to mAbsolve's new STR Fc silencing platform for antibody research and development, while ensuring favorable business terms for subsequent clinical development. The STR platform delivers the only truly silent Fc mutations described to date, offering the potential to improve the safety and efficacy of therapeutic antibodies and Fc fusion proteins.

- First and only truly Fc silent variant, described in recent PLOS One article (PMID: 34932587)
- Delivers Fc region with no detectable binding to all Fc gamma receptors (FcγRs) and C1q
- Removes Fc-mediated immune effector functions, minimizing undesirable antibody side effects
- Maintains antibody developability: stability, pharmacokinetics and immunogenicity unaffected
- STR variants can be used with a variety of species and subtypes of IgG



Figure 1. Binding of IgG1 variants to human FcγRI (CD64). STR is the first variant to completely eliminate binding to all Fc receptors, including FcγRI.



Figure 2. STR does not trigger C1q, FcγRII (CD32) or FcγRIII (CD16) receptors in cell-based assays. A) Activity in Fc receptor cell-based assays. B) Activity in a cytokine release assay.

STR Fc silencing technology joins Absolute Antibody's full portfolio of custom antibody engineering services. Control and reference antibodies featuring the STR mutations will also be available as off-the-shelf reagents in our catalog. Contact us with any questions!

Telephone: 617-377-4057 (US & Canada), +44 (0)1642 688810 (Rest of World)
Email: us-sales@absoluteantibody.com (US & Canada), sales@absoluteantibody.com (Rest of World)
Website: www.absoluteantibody.com